Abstract:BACKGROUND:Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is a recommended treatment for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) to reduce the rate of ischemic events and stent thrombosis. However, high on-treatment platelet reactivity (HTPR) during clopidogrel therapy for some patients may lead to outcome failure and occurrence of cardiovascular events. Amounts of studies have proved that genetic factors may contribute to HTPR. In our study, we explored the predictive value of 10 single nucleotide polymorphisms (SNPs) in 8 genes indicated by exome sequencing with clopidogrel efficacy. METHODS:Two hundred and forty-one Han Chinese CAD patients (mean age: 61 ± 10 years) receiving dual antiplatelet therapy were recruited, among which 118 patients administered with 300 mg loading dose (LD) clopidogrel for 12-24 h and 123 subjects administered with 75 mg/day maintain dose (MD) clopidogrel for at least 5 days before discharge. The platelet reaction index (PRI) was determined to reflect clopidogrel response in the patients. Venous blood samples were drawn from all participants to extract genomic DNA. MassARRAY, Sanger sequencing and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were used to determine the genotypes of 10 SNPs. RESULTS:Allelic tests showed significant differences in genotype distribution between HTPR and normal on-treatment platelet reactivity (NTPR) patients for 3 SNPs including CYP2C19 rs4244285 (CYP2C19*2) (co-dominant model: p = 0.003, dominant model: p = 0.004, recessive model: p = 0.012), CRISPLD1 rs12115090 (co-dominant model: p = 0.011, dominant model: p = 0.004), and LTA4H rs11108379 (dominant model: p = 0.041). After adjusting for covariates including clinical characteristics of patients, concomitant medications and complications, we confirmed that carriers of the CYP2C19*2 showed significantly increased risk of HTPR (*2/*2 vs *1/*1: OR = 12.266, 95% CI: 1.336-112.592, p = 0.027; *1/*2 + *2/*2 vs *1/*1: OR = 2.202, 95% CI: 1.083-4.480, p = 0.029). Contrarily, carriers of the CRISPLD1 rs12115090 C allele showed significantly reduced risk of HTPR (CC vs AA: OR = 0.242, 95% CI: 0.078-0.752, p = 0.014; CA + CC vs AA: OR = 0.457, 95% CI: 0.232-0.904, p = 0.024) in Chinese CAD patients. In addition, carriers of the CYP2C19*2 allele showed significantly increased PRI (*1/*2 vs *1/*1: p = 0.008, 2/*2 vs 1/*1: p < 0.001, *2/*2 vs 1/*2: p = 0.011), while patients carrying the rs12115090 C allele showed significantly decreased PRI than the wild-type AA homozygotes (CA vs AA: p = 0.046, CA + CC vs AA: p = 0.023). CONCLUSION:CYP2C19*2 reduced the antiplatelet potency of clopidogrel and increased the risk of HTPR, while CRISPLD1 rs12115090 A>C polymorphism increased the antiplatelet potency of clopidogrel. Genetic tests, especially for CYP2C19*2 are recommended in Han Chinese CAD patients before using of clopidogrel.

Association between cytochrome P450 3A4 gene 894C＞T single nucleotide polymorphism and clopidogrel resistance

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

The Association of Genetic Polymorphism with Clopidogrel Resistance among Patients after Percutaneous Coronary Intervention

Association Between CYP2C19 and ABCB1 Polymorphisms and Clopidogrel Resistance in Clopidogrel-Treated Chinese Patients

Association of N6AMT1 Rs2254638 Polymorphism with Clopidogrel Response in Chinese Patients with Coronary Artery Disease

The Association between ABCB1 Gene rs2235048 Single Nucleotide Polymorphism and Clopidogrel Resistance

Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 Polymorphisms with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke

CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.

Effect of CYP2C19 gene Polymorphism on Clopidogrel Resistance After PCI

Multivariate analysis of the correlation between the gene ploymorphisms of CYP2C19 and clopidogrel’ s resistance in Han nationality acute ischemic stroke patients

Studies on the Correlation of PON1 Gene Rs854572 Single Nucleotide Polymorphism to Clopidogrel Resistance

Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis

Study on CYP2C19 gene polymorphism and clopidogrel resistance in patients with coronary heart disease com-plicated with hypertension

Relationship of CYP2C192 and CYP2C193 Gene Polymorphism with Clopidogrel Response Variability and Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention.

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

Association between CYP3A4 gene polymorphisms and clopidogrel response in patients with cardio-cerebrovascular diseases:a systematic review and Meta-analysis

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Inhibition Of Adp-Induced Platelet Aggregation By Clopidogrel Is Related To Cyp2c19 Genetic Polymorphisms

Efffect of the ABCC3 –211C/T Polymorphism on Clopidogrel Responsiveness in Patients with Percutaneous Coronary Intervention

The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.

Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome